Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Last week in January

<< Previous

Bullboard Posts

Next >>

Comment by bringon10baggeron Jan 24, 2021 8:10pm

201 Views

Post# 32372288

RE:RE:Last week in January

Well Dan's January timeline is shortening quickly, if he was relying on the corp update and/or JP Morgan event, I guess he miserably overestimated.......this can be summarized as mgmt knowing the high probabibilty of success for phase 3 success and therefore very confident in partnering with the big boys......come on Dan share some news!

MrMugsy wrote:

Doccole wrote: Well CEO Dan said things should pickup in January. Let's see if there is any news this week. Hoping for a nasdq uplisting information release.

Going to guess the order will be more in line with this ...

- more value generation in drug development
- more value generation for existing drugs (in the lab - including dosing trial decisions)
- partnering in smaller geographies
- share price increase due to above
- co-listing consideration